抗抑郁治疗对老年高血压降压疗效的影响

该文探讨抗抑郁治疗对老年高血压患者降压疗效的影响。方法:对138例老年高血压合并抑郁的患者随机分为A、B组,并设老年高血压患者对照组103例,3组均给予氢氯噻嗪12.5mg/d和硝苯地平控释片30mg/d口服,A组在此基础上加服氟西汀(百优解)20mg/d口服,共12周;B组给予阿米三嗪(都可喜)1片和谷维素20mg,3次/d,共12周。结果:A组与治疗前及B组相比,其坐位血压、24h动态血压监测昼夜收缩压和舒张压均明显下降,差异有非常显著意义(P<0.01)。结论:抗抑郁治疗有利于老年高血压合并抑郁患者的血压控制。抗抑郁治疗对老年高血压降压疗效的影响…     

抗抑郁治疗对老年高血压降压疗效的影响

目的探讨抗抑郁治疗对老年高血压患者降压疗效的影响。方法对138例老年高血压合并抑郁的患者随机分为A、B组,并设103例老年高血压患者对照组,三组均给予氢氯噻嗪12．5mg／d和硝苯地平控释片30mg／d口服,A组在此基础上加服氟西汀20mg／d口服,共12周;B组给予阿米三嗪1片和谷维素20mg,3次／d,共12周。结果A组与治疗前及B组相比,其坐位血压、24h动态血压监测昼夜收缩压和舒张压均明显下降,差异有显著的统计学意义（P〈0．01）。结论抗抑郁治疗有利于老年高血压合并抑郁患者的血压控制。     

抗抑郁治疗对老年高血压降压疗效的影响

该文探讨抗抑郁治疗对老年高血压患者降压疗效的影响。方法：对138例老年高血压合并抑郁的患者随机分为A、B组，并设老年高血压患者对照组103例，3组均给予氢氯噻嗪12．5mg／d和硝苯地平控释片30mg／d口服，A组在此基础上加服氟西汀（百优解）20mg／d口服，共12周；B组给予阿米三嗪（都可喜）1片和谷维素20mg，3次／d，共12周。结果：A组与治疗前及B组相比，其坐位血压、24h动态血压监测昼夜收缩压和舒张压均明显下降，差异有非常显著意义（P〈0.01）。结论：抗抑郁治疗有利于老年高血压合并抑郁患者的血压控制。     

洛汀新与施慧达联合治疗糖尿病合并高血压临床观察

将119例糖尿病合并高血压患者随机分为A、B、C组.A组口服洛汀新5～10 mg,1 次/d;B组口服施慧达2.5～5 mg,1 次/d;C组口服洛汀新5 mg与施慧达2.5 mg,1 次/d.三组均治疗8周.观察降压疗效,并采用放免法测定治疗前后尿白蛋白排泄率(UAER).结果 显示,C组降压效果优于A、B组;各组治疗后UAER水平均有所下降,且C组较B组下降明显.认为洛汀新联合施慧达治疗糖尿病合并高血压疗效更佳.     

综合干预对老年高血压伴抑郁症患者血压的影响

目的：探讨综合干预对老年高血压伴抑郁患者血压的影响。方法：70例老年高血压件抑郁症患者随机分为二组，综合干预组35例，给予降压、抗抑郁治疗及心理疏导，健康教育；常规治疗对照组35例，仅给予降压及抗抑郁治疗。分别了入院时和治疗6周对两组患者的降压效果及抑郁自我评定量表（SDS）分值进行评价。结果：综合干预组血压控制效果及SDS分值改善均显著优于常规治疗对照组（P〈0．05，〈0．01）。结论：对老年高血压伴抑郁患者进行综合干预治疗，不仅能改变患者的治疗态度，提高患者对治疗的依从性，还能明显提高血压控制率，改善SDS分值。     

降压降脂联合治疗对老年高血压患者动脉弹性的影响

目的探讨降压降脂联合治疗对老年高血压患者动脉弹性的影响。方法入选老年轻、中度高血压患者216例,给予氢氯噻嗪(双氢克尿噻)(25 mg/d)作为基础治疗,2 w后随机分为联合组、降压组及降脂组,每组72例。分别给予坎地沙坦(8 mg/d)和(或)瑞舒伐他汀(10 mg/d)降压、降脂治疗12个月。测量血压、血生化、颈桡脉搏波传导速度。结果治疗12个月后,三组桡动脉脉搏波传导速度均较治疗前降低(P<0.05),联合组下降幅度较降压组、降脂组显著(P<0.05)。结论降压联合降脂治疗能显著降低老年高血压患者的颈桡脉搏波传导速度,改善动脉弹性,强于单一的降压或降脂治疗。     

西酞普兰治疗老年慢性心力衰竭合并抑郁患者的临床观察

目的 研究西酞普兰在治疗老年慢性心力衰竭合并抑郁患者的临床效果.方法 选取2019年1月?2020年1月于我院急诊科和老年医学科住院的老年慢性心力衰竭合并抑郁患者191例,将患者随机分为对照组95例和观察组96例(西酞普兰10 mg,1次/d),2组患者均给予常规对症治疗.所有患者均行老年抑郁评分(geriatric ...     

抗抑郁治疗对老年不稳定型心绞痛伴抑郁患者近期预后的影响

目的观察抗抑郁治疗对老年不稳定型心绞痛伴抑郁患者近期预后的影响.方法将老年不稳定型心绞痛伴抑郁的患者随机分为抗抑郁治疗组和对照组各31例,治疗组在常规心脏病药物治疗基础上给予心理治疗及加服抗抑郁药盐酸舍曲林(左洛复)50mg/d,共12周;对照组给予单纯常规心脏病药物治疗.结果治疗组心肌缺血明显改善,心绞痛复发率及发生急性心肌梗死比率低,与对照组比较,有显著性差异(P＜0.05).结论抗抑郁治疗能明显改善不稳定型心绞痛伴抑郁患者的近期预后.     

严格血压控制对1级高血压合并糖尿病老老年患者尿微量白蛋白的影响

目的 探讨将收缩压控制在140 mm Hg以下对1级高血压合并2型糖尿病80岁以上高龄老人尿微量白蛋白的影响.方法 1级高血压合并2型糖尿病伴尿微量白蛋白阳性老老年(≥80岁)门诊或住院患者70例,按就诊顺序随机分降压治疗组(35例)和常规治疗组(35例),降压治疗组在常规治疗的基础上加服厄贝沙坦( 150 mg/d)...     

抗抑郁治疗对老年高血压合并抑郁障碍患者血压的影响

正该文研究抗抑郁治疗对老年高血压合并抑郁障碍患者血压的影响及其改善生活质量的临床疗效。方法:老年高血压合并抑郁障碍患者304例,随机分为治疗组156例和对照组148例,分别给予盐酸曲唑酮和盐酸曲唑酮模拟药,2组治疗4周,观察治疗前和治疗后第1、2、3、4周患者血压、17项汉密尔顿抑郁量表     

Comparison of monotherapy versus combination antihypertensive therapy in elderly patients with essential hypertension

Authors sought to compare the efficacy of monotherapy versus combination antihypertensive therapy in elderly patients. Patients in this study, aged 65 to 85 years, were divided into 4 groups and entered an 8-week treatment period. First group: 22 patients, amlodipine 5 mg/d increasing to 10 mg; second: 20 patients, eprosartan 600 mg/d increasing to 600 mg twice a day; third: 21 patients, amlodipine 5 mg/d and indapamide 2.5 mg/d, increasing amlodipine to 10 mg/d; fourth: 23 patients, imidapril 10 mg/d and indapamide 2.5 mg/d, imidapril doubled to 20 mg/d. A greater drop in systolic and in diastolic blood pressure was obtained by combination of amlodipine and indapamide compared with amlodipine or eprosartan monotherapy. Imidapril and indapamide showed similar efficacy compared with eprosartan monotherapy but not with amlodipine monotherapy. Amlodipine and indapamide appeared more effective than imidapril and indapamide in diastolic blood pressure. Combination treatment with amlodipine and indapamide or imidapril and indapamide effectively reduces blood pressure in elderly patients with essential hypertension.     

左旋氨氯地平和氨氯地平治疗轻中度高血压的临床观察

目的评价左旋氨氯地平和氨氯地平治疗轻中度高血压的疗效与不良反应。方法选择门诊轻中度高血压患者108例,随机分为3组,每组36例,接受氨氯地平5 mg/d(A组)、左旋氨氯地平2.5 mg/d(B组)、左旋氨氯地平5 mg/d(C组),共治疗8周,观察降压效果和不良反应。结果 3组治疗后收缩压和舒张压较治疗前明显下降(P<0.05)。与A、B组比较,C组血压变化值更高(P<0.01),血压达标率高(P<0.05)。3组治疗后红细胞计数、血红蛋白较治疗前明显增高(P<0.05);B组血K~+明显降低(P<0.05)。结论左旋氨氯地平能有效降低轻中度高血压患者的血压,不良反应低于氨氨地平,左旋氨氯地平2.5 mg治疗后血K+下降。     

吲达帕胺及(或)非洛地平对老年高血压患者动态血压的影响

目的探讨降压药物吲达帕胺缓释片联合非洛地平缓释片在老年高血压患者中的降压效果。方法选择老年高血压病患者150例,平均年龄(65±4)岁,按就诊顺序随机分3组:分别给予吲达帕胺缓释片1.5mg/d、非洛地平缓释片5mg/d和吲达帕胺缓释片1.5mg/d+非洛地平缓释片5mg/d,疗程3个月。观察治疗前后24h、白昼及夜间平均收缩压/舒张压和平均收缩压/舒张压负荷以及平均心率。结果治疗结束时3组24h、白昼和夜间平均收缩压/舒张压均较服药前明显下降;血压负荷值亦明显减少;而联合治疗组与单药治疗组比较下降更明显,差异具有统计学意义。治疗前后心率没有明显变化。结论小剂量长效利尿剂联合钙拮抗剂治疗高血压疗效显著,稳定性好,不良反应少。老年高血压病患者应尽量选择长效利尿剂联合钙拮抗剂。     

阿托伐他汀对男性高血压患者勃起功能障碍的影响

目的探讨阿托伐他汀对男性高血压患者勃起功能障碍(ED)的影响。方法入选我院2003-07-2006-06收治的男性轻中度高血压病人838例,随机分为两组:常规降压(对照组,n=374)和常规降压+阿托伐他汀(治疗组,n=369)。两组均先给予硝苯地平缓释片+依那普利进行常规降压治疗,如血压不能达标,加用氢氯噻嗪12.5mg/d。降压达标后治疗组加用阿托伐他汀10mg/d,对照组治疗方案不变。每4周随访1次,总共随访36周,调查分析治疗前后ED患病情况。结果治疗组有369例,对照组有374例完成随访,治疗前两组的ED患病率为60.2%vs60.9%(P>0.05),差异无统计学意义。治疗后加用阿托伐他汀组的ED患病率为46.3%vs对照组63.7%(P<0.01),差异有非常显著意义。结论阿托伐他汀可改善男性高血压患者勃起功能障碍。     

Use of an olmesartan medoxomil-based treatment algorithm for hypertension control

Hypertension guidelines recommend a steppedcare approach that starts with titration of the initial agent followed by the addition of other agents, as necessary, to achieve goal blood pressure. This study assessed the effectiveness of an antihypertensive treatment algorithm with olmesartan medoxomil as the initial agent. This was a 24-week, open-label trial in patients (N=201) with mean seated diastolic blood pressure of 90–109 mm Hg. Following placebo run-in, all patients received olmesartan medoxomil 20 mg/d for 4 weeks. At subsequent 4-week intervals, the regimen was modified in patients with blood pressure >130/85 mm Hg: up-titration of olmesartan medoxomil to 40 mg/d; addition of hydrochlo-rothiazide 12.5 mg/d; up-titration of hydrochlo-rothiazide to 25 mg/d; addition of amlodipine besylate 5 mg/d; and up-titration of amlodipine besylate to 10 mg/d. Patients who achieved blood pressure ≤130/85 mm Hg at any point exited the study with no further follow-up. At Week 24, reductions in blood pressure from baseline were 33.7/18.2 mm Hg. Altogether, 87.7% of patients reached the goal blood pressure of ≤130/85 mm Hg and 93.3% achieved a blood pressure of ≤140/90 mm Hg. Thus, an antihypertensive algorithm with olmesartan medoxomil as the initial agent controlled blood pressure in the majority of patients, but with >60% of patients also requiring the use of a thiazide diuretic or a thiazide and a calcium channel blocker.     

The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study

Background: Combined treatment of a calcium antagonist and α/β-adrenoreceptor blocker is expected to offer some advantages in the management of hypertension; however, their antihypertensive efficacy and safety remain relatively under-explored.

Methods: The current study addresses the 24-h antihypertensive efficacy and safety of arotinolol combined with a different calcium channel blocker. One-hundred fifty-two patients were randomly divided into three groups: nifedipine, amlodipine and felodipine group. In each group, the antihypertensive treatment dose was 30?mg/d, 5?mg/d, 5?mg/d long acting nifedipine, amlodipine, felodipine plus 20?mg/d arotinolol, respectively. Blood pressure was measured in ABPM devices and mercury manometer.

Results: The result showed that the effective rate of one year antihypertensive treatment of arotinolol combined with nifedipine was 51 of 53, significantly effective (p?p?>?0.05) in controlled rate of morning peak blood pressure between treatment of arotinolol combined with amlodipine and arotinolol combined with nifedipine, but there was a significant difference (p?Conclusions: The therapy approached of arotinolol combined with nifedipine or amlodipine could be effective and well-tolerated, and they can be used as the better chosen antihypertensive drug.     

普罗布考对原发性高血压患者血红素氧合酶1表达的影响

目的:探讨普罗布考对高血压患者血清血红素氧合酶1(HO-1)水平的影响和意义。方法:筛选40例原发性高血压患者,随机分为两组,分别接受以下药物治疗:苯磺酸左旋氨氯地平2.5mg/d+贝那普利10mg/d(对照组,20例),苯磺酸左旋氨氯地平2.5mg/d+贝那普利10mg/d+普罗布考组500mg/d(实验组,20例);同时入选健康体检者作为健康组(20例),随访4周。采用酶联免疫吸附法(ELISA)测定血清中HO-1的水平,观察比较3组血压、血脂和肝肾功能。结果:实验组和对照组血清HO-1水平明显高于健康组(P<0.05);与对照组相比,实验组TC、LDL-C及HDL-C明显降低(P<0.05);治疗后实验组及对照组血清HO-1水平下降,实验组下降更明显。结论:高血压患者血清HO-1水平显著升高,而普罗布考治疗可以改善高血压患者氧化应激状态,下调其血清HO-1水平,更有助于血压控制。     

绝经后激素替代治疗对脂代谢及胰岛素抵抗的影响

目的　观察激素替代治疗(HRT)对绝经后高血压妇女的血压、脂代谢及胰岛素抵抗的影响。方法　选择绝经后轻、中度高血压妇女共 50 例。随机分成降压治疗组 25 例、降压治疗 HRT组(联合治疗组)25 例。两组均予口服福辛普利 10 mg/d 或福辛普利 10 mg/d 寿比山 2 5mg/d降压治疗;联合治疗组加服替勃龙(Tibolone)2 5 mg/d作为激素替代治疗,两组平均连续用药9月,观察治疗前后血压、血脂、胰岛素敏感指数(ISI)的变化。另设绝经后正常血压组22例作为对照组。　结果　1.治疗前绝经后高血压患者 ISI较对照组明显降低(P<0 .01)。降压治疗组在治疗后收缩压(SBP)和舒张压(DBP)较治疗前分别下降了12. 3%和15 7%;联合治疗组SBP和DBP较治疗前分别下降14 8%和17 2%,两组差异不显著(P>0. 05)。2.降压治疗组治疗前后血脂无明显变化;联合治疗组治疗后的总胆固醇(TC)下降 13 2%(P<0. 05),脂蛋白 a(Lpa)下降 33 3%(P<0 .01)。甘油三酯(TG)有上升的趋势,但无显著性差异(P> 0 05)。3.降压治疗组 ISI 上升 18 1% (P<0 .05),联合治疗组ISI下降了20 3%(P<0 .01),两组差异显著(P<0 .01)。结论　1.替勃龙联合降压药物治疗绝经后高血压对降压疗效无影响。2.能明显降低血总胆固醇及脂蛋白(a),对心脑血管疾病可能有益。3.绝经后高血     

氯沙坦、福辛普利及硝苯地平控释剂对原发性高血压患者诊所血压及24小时动态血压作用之比较

目的探讨氯沙坦、福辛普利和硝苯地平控释剂对原发性高血压患者诊所血压及昼夜血压的影响,并进行比较.方法87例轻、中度原发性高血压患者随机分为3组,分别服用氯沙坦50?mg/d(L组,30例)、福辛普利10?mg/d(F组,28例)和硝苯地平控释剂30?mg/d(N组,29例),比较治疗前及治疗4周末对诊所血压(OBP)[BFQ、动态血压的影响.结果3组治疗4周末OBP、动态血压均较服药前降低,有显著性差异([WTBXP＜0.05～0.001),3组间无显著性差异;各组均能维持正常的血压昼夜节律,24小时血压谷/峰(T/P)均大于70%;以N组作用显著.各组不良反应发生率分别为F组39.4%、N组43.8%、L组18.2%,N组24小时平均心率较治疗前明显加快(P＜0.05).结论氯沙坦、福辛普利和硝苯地平控释剂均能有效持续降低血压.治疗后硝苯地平控释剂24小时血压谷/峰优于氯沙坦和福辛普利.氯沙坦服药后的耐受性优于福辛普利及硝苯地平控释剂.